Haemostatic activation in post-menopausal women taking low-dose hormone therapy: Less effect with transdermal administration?

Summary

Hormone therapy (HT) increases the risk of cardiovascular and thromboembolic disease in post-menopausal women. Recent studies have suggested that prothrombotic mechanisms are likely to be involved. Transdermal HT avoids the first-pass effect of oestrogen in the liver and may have a less marked effect on the haemostatic system than equivalent oral preparations. The majority of studies have compared HT preparations that have different formulations as well as routes of administration. We investigated changes in the haemostatic system in post-menopausal women using two pharmacologically similar HT preparations, which differed only in their route of administration. Three hundred forty-four healthy post-menopausal women were randomised to six months treatment with either a transdermal matrix patch containing 25 µg 17 β -estradiol/125 µg norethisterone acetate (NETA) applied every 3–4 days, or an equivalent oral preparation (estradiol 1mg and NETA 0.5 mg given once daily). Oral treatment significantly reduced fibrinogen (p<0.003), factor VIIc (FVIIc) (p<0.00001), and antithrombin (AT) levels (p<0.005); the effects in the transdermal group were less marked with no reduction in fibrinogen levels and lesser effect on FVIIc (p<0.03) compared with oral treatment. Treatment type significantly affected fibrinolysis with lower plasminanti- plasmin (PAP) levels in the transdermal group (p<0.003) and lower plasminogen activator inhibitor-1 antigen (PAI-1) (p<0.012) and tissue plasminogen activator (tPA) antigen levels in the oral group (p<0.002). Prothrombin fragment 1.2 and activated protein C (APC) resistance were not affected by either treatment. Transdermal HT has a less marked effect on coagulation than an equivalent oral preparation. Randomised trials are required to investigate whether this translates into less risk of cardiovascular and thromboembolic disease.

Keywords

Transdermal hormone therapy - coagulation - fibrinolysis - menopause

• References

• 1 Stampfer M, Colditz G, Willeltt W. et al. A prospective study of postmenopausal estrogens therapy and cardiovascular disease: Ten-year follow up form the Nurse's health Study. N Engl J Med 1991; 325: 756-762.
• 2 Bush T. The epidemiology of cardiovascular disease in postmenopausal women. Ann NY Acad Sci 1990; 592: 263-271.
• 3 Grodstein F, Stampfer M, Colditz G. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769-1775.
• 4 Mendelsohn ME, Karas RH. Mechanisms of disease. The protective effects of estrogens on the cardiovascular system. N Engl J Med 1999; 340: 1801-1811.
• 5 Writing Group for the Women's Health Initiative I Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal Results From the Women's Health Initiative Randomized Controlled Trial. J Am Med Assoc 2002; 288: 321-333.
• 6 Hulley S, Grady D, Bush T. Randomised trial of estrogens plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement (HERS). J Am Med Assoc 1998; 280: 605-613.
• 7 Sagripanti A, Carpi A. Natural anticoagulants, aging, and thromboembolism. Exp Gerontol 1998; 33: 891
• 8 Cushman M KL, Prentice R, Rodabough RJ. et al. Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. J Am Med Assoc 2004; 292: 1573-1580.
• 9 Scarabin P-Y, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428-432.
• 10 Modena MG, Sismondi P, Mueck AO. et al. New evidence regarding hormone replacement therapies is urgently required: Transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas 2005; 52: 1-10.
• 11 Chetkowski R, Meldrum D, Steingold K. et al. Biologic effects of Transdermal estradiol. N Engl J Med 1986; 314: 1615-1620.
• 12 Hoibraaten E, Os I, Seljeflot I. et al. The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: Results from the Estrogen in Women with Atherosclerosis Study. Thrombus Res 2000; 98: 19-27.
• 13 Seljeflot I, Arnesen H, Hofstad A-E. et al. Reduced expression of endothelial cell markers after long-term transdermal hormone replacement therapy in women with coronary artery disease. Thromb Haemost 2000; 83: 994-948.
• 14 Stevenson JC, Oladipo A, Manassiev N. et al. Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. Br J Haematol 2004; 124: 802-808.
• 15 Martinez C, Basurto L, Zarate A. et al. Transdermal estradiol does not impair hemostatic biomarkers in postmenopausal women. Maturitas 2005; 50: 39-43.
• 16 Perera M, Sattar N, Petrie JR. et al. The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: A randomized, placebo-controlled study. J Clin Endocrinol Metab 2001; 86: 1140-1143.
• 17 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmumg des Fibrinogens. Acta Haematol 1957; 17: 237-246.
• 18 Giddings J. Heriditary coagulation disorders. Laboratory techniques. In: A practicle guide to blood coagulation and haemostasis. London: Churchill Livingstone; 1980
• 19 Odegard O, Fagerhol M, Lie M. Heparin cofactor activity measured with an amidolytic method. Thromb Haemost 1975; 6: 287-294.
• 20 Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. PNAS 1993; 90: 1004-1008.
• 21 Pelzer H, Schwarz A, Stuber B. Determination of human prothrombin activation fragment 1.2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991; 65: 153-159.
• 22 Pelzer H, Pilgrim A, Schwarz A. et al. Determination of &#x 03B1;2-antiplasmin-plasmin complex in human plasma with an enzyme-linked immunosorbent assay. Fibrinolysis 1993; 7: 69-74.
• 23 DeClerk P, Alessi M, Verstreken M. et al. Measurement of plasminogen activator inihibitor I in biologic fluids with a murine monoclonal antibody-based enzyme linked immunosorbent assay. Blood 1988; 71: 220-225.
• 24 Bergsdoft N, Nilsson T, Wallen P. An enzyme linked immunosorbent assay for determination of tissue plasminogen activator applied to patients with thromboembolic disease. Thromb Haemost 1983; 50: 740-745.
• 25 Samsioe G, Dvorak V, Genazzani AR. et al. Oneyear endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low dose estradiol norethisterone acetate (NETA) in postmenopausal women. Maturitas 2007.(in press).
• 26 Lowe GDO, Upton MN, Rumley A. et al. Different effect of oral and transderaml hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein. A cross sectional population survey. Thromb Haemost 2001; 86: 550-556.
• 27 Nabulsi AA, Folsom AR, White A. et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328: 1069-1075.
• 28 Norris LA, Joyce M, O'Keeffe N. et al. Haemostatic risk factors in healthy postmenopausal women taking hormone replacement therapy. Maturitas 2002; 43: 125-133.
• 29 Taner MZ, Ozpolat E, Taskiran C. et al. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: A prospective randomized study. Maturitas 2006; 53: 267
• 30 Zegura B, Keber I, Sebestjen M. et al. Orally and transdermally replaced estradiol improves endothelial function equally in middle-aged women after surgical menopause. Am J Obstet Gynecol 2003; 188: 1291-1296.
• 31 Post M, van der Mooren M, van Baal W. et al. Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: A randomized placebo-controlled study. Am J Obstet Gynecol 2003; 189: 1221-1227.
• 32 Seed M, Sands RH, McLaren M. et al. The effect of hormone replacement therapy and route of administration on selected cardiovascular risk factors in postmenopausal women. Fam Pract 2000; 17: 497-507.
• 33 Vehkavaara S, Silveria A, Hakala-Ala-Pietila T. et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001; 85: 619-625.
• 34 Scarabin P-Y, Alhenc-Gelas M, Plu-Bureau G. et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17: 3071-3078.
• 35 Di Biotondo R, Hall A, Peake IR. et al. Oestrogenic repression of human coagulaton factor VII expression mediated through an osetrogen response element sequence motif in the promoter region. Hum Mol Genet 2002; 11: 723-731.
• 36 Bucciarelli P, Rosendaal FR, Tripodi A. et al. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: A multicenter collaborative family Study. Arterioscler Thromb Vasc Biol 1999; 19: 1026-1033.
• 37 Salobir BG, Keber I, Vrabic L. A randomized, placebo-controlled trial of the effects of continuous combined hormone replacement therapy on coagulation and fibrinolytic systems in healthy postmenopausal women. Fertil Steril 2002; 78: 1178-1183.
• 38 Lowe GDO, Woodward M, Vessey M. et al. Thrombotic variables and the risk of idiopathic venous thrombolism in women aged 45–64 years: relationships to hormone replacement therapy. Thromb Haemost 2000; 83: 530-535.
• 39 Nicolaes G, Dahlback B. Congenital and acquired activated protein C resistance. Semin Vasc Med 2003; 3: 333-346.
• 40 Peverill RE. Hormone therapy and venous thromboembolism. Best Pract Res Clin Endocrinol Metabol 2003; 17: 149-164.
• 41 Oger E, Alhenc-Gelas M, Lacut K. et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: A randomized trial. Arterioscler Thromb Vasc Biol 2003; 23: 1671-1676.
• 42 Post MS, Christella M, Thomassen LGD. et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: A randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003; 23: 1116-1121.
• 43 Norris LA. Blood coagulation. Best Pract Res Clin Obst Gynaecol 2003; 17: 369-383.
• 44 Osmanagaoglu MA, Osmanagaoglu S, Osmanagaoglu T. et al. Effect of different preparations of hormone therapy on lipid and glucose metabolism, coaguloation factors, bone mineral density in overweight and obese postmenopausal women. Fertil Steril 2005; 84: 384-392.
• 45 Zegura B, Keber I, Sebestjen M. et al. Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis. Atherosclerosis 2003; 168: 123
• 46 McKenzie J, Jaap AJ, Gallacher S. et al. Metabolic, inflammatory and haemostatic effects of a low dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk?. Clin Endocrinol 2003; 59: 682-689.
• 47 Chomiki N, Henry M, Alessi MC. et al. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel wall. Thromb Haemost 1994; 74: 44-53.
• 48 Koh KK, Mincemoyer R, Bui MN. et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336: 683-691.
• 49 Madsen J, Kristensen SR, Gram J. et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long-term randomized controlled study in healthy postmenopausal women. J Thromb Haemost 2003; 1: 1984-1991.
• 50 Harmam SM, Brinton E, Cedars M. et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005; 8: 3-12.